The 2026 Alzheimer’s clinical trials pipeline shows a strategic shift from amyloid to inflammation and tau targets, with combination therapies and repurposed drugs leading the way. In 2026, the Alzh...
Alzheimer’s Drug Development Revolution: Inflammation and Tau Take Center Stage as Amyloid Era Fades
The 2024 pipeline report reveals a dramatic shift from amyloid to inflammation and tau targets, with repurposed drugs and combination therapies leading a new era of Alzheimer’s treatment. New re...
A new study reveals that dasatinib and quercetin (D+Q) cause demyelination in mice, raising safety concerns as over 30 clinical trials test the combo for age-related diseases. A study in Nature Aging ...
Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
A recent DGIST study shows somatostatin overexpression reduces inflammation and amyloid β in mice, suggesting repurposing existing drugs like octreotide could accelerate Alzheimer’s therapy and...
Phase 1 trial of RLS-1496 demonstrates safety with no severe adverse events and significant reduction in inflammatory markers, highlighting its potential as a senolytic therapy for skin conditions lik...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
